Comparison of fluid and flunixin meglumine therapy in combination and individually in the treatment of toxic mastitis

Green, M. J.; Green, L. E.; Cripps, Peter

doi:10.1136/vr.140.6.149

Cited by 18 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These results are similar to those reported in bovine mastitis, after administration of nonsteroidal anti-inflammatory agents (Anderson & Hunt, 1989;Green et al, 1997;Morin et al, 1998). Furthermore, administration of flunixin without antibacterial agents is often practiced.…”

supporting

confidence: 91%

Field evaluation of flunixin meglumine in the supportive treatment of caprine mastitis

Mavrogianni¹,

Alexopoulos²,

Fthenakis³

2004

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

supporting

confidence: 91%

Field evaluation of flunixin meglumine in the supportive treatment of caprine mastitis

Mavrogianni¹,

Alexopoulos²,

Fthenakis³

2004

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

“…The rate of reduction of MRTemp and of MTCRS in group A ewes were significantly greater (PB0.01) than that in group B ewes. A statistically significant difference was observed among These results are similar to ones found in bovine mastitis, for the treatment of which administration of non-steroid anti-inflammatory agents is recommended (Anderson & Hunt, 1989;Green et al, 1997;Morin et al, 1998). Furthermore, dosage of flunixin without antibiotics is often practised.…”

supporting

confidence: 77%

Field evaluation of flunixin meglumine in the supportive treatment of ovine mastitis

Fthenakis

2000

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Non-steroid anti-inflammatory agents are used in the treatment of bovine coliform mastitis, in order to reduce the severity of the clinical signs, to improve cure and to minimize the adverse effects of the disease (Lohuis et al., 1989;Morin et al., 1998). In ewes, similar findings have not been reported and consequently, the efficacy of these drugs in the treatment of ovine mastitis is not known. The objective of this study was the evaluation of flunixin meglumine (FINADYNE ® Schering-Plough) in the supportive treatment of ovine mastitis.Sixty dairy ewes of various ages and local Greek breeds, with spontaneous acute clinical mastitis were included into the study. To account for the likely flock-effect and to improve the efficiency of the study in terms of the amount of information per subject studied, a matched case-control sampling design was followed (Rothman & Greenland, 1998). The matching factor was the flock of origin; within each flock and for every case-ewe (i.e. a ewe with acute clinical mastitis) the first ewe with acute clinical mastitis after the case-ewe was selected as control.Ewes were allocated into group A (test) or B (control) (n= 30). Ewes in group A were treated with cefuroxime (SPEC-TRAZOL ® , Schering-Plough) and with flunixin meglumine simultaneously and those in group B with cefuroxime only. Cefuroxime was administered intramammarily on three occasions, every 12 h, and the dose was 250 mg (one tube) per occasion per ewe. Flunixin meglumine was administered intramuscularly on two occasions, with a 24 h period between, and the dose was 100 mg (1.82-2.33 mg/kg body weight) per occasion per ewe. Treatment was instigated within 30-60 h after the initial observation of the signs of mastitis (abnormal secretion, swollen mammary gland, change of colour of the udder skin etc.) by the farmer.Before treatment (D0) an initial clinical examination of each ewe was carried out and mammary secretion samples were collected. The rectal temperature was recorded and the mammary glands were examined. Seven different mammary or systemic reactions were observed and scored on a 0 (no reaction) to 4 (very severe reaction) scale (Table 1). The total clinical reaction score was produced by addition of all mammary and systemic reactions scores and ranged from 0 to 28. Subsequently, clinical examination and collection of mam-mary secretion samples were carried out 1 day (D1), 2 days (D2), 4 days (D4) and 14 days (D14) after initiation of the treatment. Mammary secretion samples were examined bacteriologically by using conventional methods (Fthenakis, 1988(Fthenakis, , 1994.The clinical cure rate of each group was the proportion of ewes without clinically detectable abnormal signs. The bacteriological cure rate of each group was the proportion of ewes with no bacteria isolated from mammary secretion samples. The mean rectal temperature (MRTemp) in each group was calculated as: MRTemp= (Temp 1 + Temp 2 + …+Temp n )/n, and the mean total clinical reaction score (MTCRS) in each group was calculated as: MTCRS=(S 1 + S 2 + ...

show abstract

“…In severe clinical mastitis, i.v. fluid, electrolyte, or dextrose treatment, as well as other supportive treatments, are often used in order to save the cow (Green et al ., ). The efficacy of these treatments has not been systematically assessed.…”

Section: Characteristics Of Escherichia Coli Mastitismentioning

confidence: 99%

“…Few field studies on antimicrobial treatment for E. coli mastitis have been published and their results are equivocal (Shpigel et al, 1994;Suojala et al, 2010). Non-antimicrobial treatments have been suggested as alternatives to antimicrobials for treating E. coli mastitis, including glucocorticoids, nonsteroidal anti-inflammatory drugs (NSAIDs), frequent milking, fluid therapy and lactoferrin (Green et al, 1997;Erskine et al, 2003;Kutila et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

Treatment for bovineEscherichia colimastitis – an evidence‐based approach

Suojala

Kaartinen

Pyörälä

2013

Vet Pharm & Therapeutics

137

110

View full text Add to dashboard Cite

Bovine mastitis caused by Escherichia coli can range from being a subclinical infection of the mammary gland to a severe systemic disease. Cow-dependent factors such as lactation stage and age affect the severity of coliform mastitis. Evidence for the efficacy of antimicrobial treatment for E. coli mastitis is very limited. Antimicrobial resistance is generally not a limiting factor for treatment, but it should be monitored to detect changes in resistance profiles. The only antimicrobials for which there is some scientific evidence of beneficial effects in the treatment for E. coli mastitis are fluoroquinolones and cephalosporins. Both are critically important drugs, the use of which in animals destined for food should be limited to specific indications and should be based on bacteriological diagnosis. The suggested routine protocol in dairy herds could target the primary antimicrobial treatment for mastitis, specifically infections caused by gram-positive bacteria. In E. coli mastitis with mild to moderate clinical signs, a non-antimicrobial approach (anti-inflammatory treatment, frequent milking and fluid therapy) should be the first option. In cases of severe E. coli mastitis, parenteral administration of fluoroquinolones, or third- or fourth-generation cephalosporins, is recommended due to the risk of unlimited growth of bacteria in the mammary gland and ensuing bacteremia. Evidence for the efficacy of intramammary-administered antimicrobial treatment for E. coli mastitis is so limited that it cannot be recommended. Nonsteroidal anti-inflammatory drugs have documented the efficacy in the treatment for E. coli mastitis and are recommended for supportive treatment for clinical mastitis.

show abstract

Comparison of fluid and flunixin meglumine therapy in combination and individually in the treatment of toxic mastitis

Cited by 18 publications

References 11 publications

Field evaluation of flunixin meglumine in the supportive treatment of caprine mastitis

Field evaluation of flunixin meglumine in the supportive treatment of caprine mastitis

Field evaluation of flunixin meglumine in the supportive treatment of ovine mastitis

Treatment for bovineEscherichia colimastitis – an evidence‐based approach

Contact Info

Product

Resources

About